Private hospital chains Fortis Healthcare and Apollo Hospitals have started administering Russian COVID-19 vaccine Sputnik V at two of their hospitals in Delhi-NCR, officials said.
Benchmark BSE Sensex and Nifty closed lower by nearly 1 per cent on Tuesday amid fresh foreign fund outflows and mixed global trends. The 30-share BSE benchmark fell by 497.73 points or 0.89 per cent to settle at 55,268.49, extending its losses for second straight day. During the day, it tanked 562.79 points or 1 per cent to 55,203.43. The broader NSE Nifty declined by 147.15 points or 0.88 per cent to 16,483.85.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
In a continuing trend for the previous two quarters, foreign currency fluctuations and mark-to- market losses are affecting profits of India's drug makers, despite increase in net sales ranging between 4.5 and 42 per cent for most of the firms during the three-month period.
'Nobody asked us to work on this. It was on our own that we decided to embark on this journey.'
As many as 24 special economic zone (SEZ) developers including Dr Reddy's Lab and Tata Consultancy Services have sought more time from the government to execute their projects.
The Sensex closed up 22.50 points or 0.16% at 13,703.33, and the Nifty up 5.40 points or 0.14% at 3950.85.
The markets opened in the positive terrain but slipped and are trading flat as selling was seen in banking and pharma stocks
The markets opened in the positive terrain after seeing a flat close yesterday
Benchmark indices bounced back after falling in early trade on Thursday and logged the fifth day of gain amid a decline in crude oil prices and foreign funds inflow. The 30-share BSE Sensex climbed 284.42 points or 0.51 per cent to settle at 55,681.95. During the day, it jumped 340.96 points or 0.61 per cent to 55,738.49. The broader NSE Nifty went higher by 84.40 points or 0.51 per cent to 16,605.25.
Benchmark stock indices Sensex and Nifty spurted over 1 per cent at close on Monday following buying in IT, oil and gas and banking shares bolstered by firm global trends. Rising for a second straight session, the 30-share BSE Sensex rallied 760.37 points or 1.41 per cent to settle at 54,521.15. During the day, it jumped 795.88 points or 1.48 per cent to 53,760.78. The broader NSE Nifty advanced 229.30 points or 1.43 per cent to 16,278.50 as 41 of its constituents advanced.
The BSE Sensex opened with a positive gap of 10 points at 5,179. Fresh buying in the markets led the index spurt to a high of 5,204. The index is now at 5,195, up 26 points. The Nifty is up 7 points at 1,634.
Benchmark indices turned highly volatile in the last hour of trade on Monday, with the Sensex falling 86.61 points after three days of gain amid heavy selling in IT counters and weak trends in global markets. The 30-share BSE benchmark declined 86.61 points or 0.16 per cent to settle at 54,395.23. During the day, it fell by 391.31 points or 0.71 per cent to 54,090.53.
Benchmark indices Sensex and Nifty gave up early gains to close lower for a fourth straight session on Thursday due to selling in IT and banking shares amid weak global equities. The 30-share BSE benchmark settled 98 points or 0.18 per cent lower at 53,416.15. During the day, it hit a high of 53,861.28 and a low of 53,163.77. The broader NSE Nifty also pared initial gains and ended 28 points or 0.18 per cent down to settle at 15,938.65.
Indices reversed all its losses during late trades.
Analysts feel this decision is yet another example of big-ticket acquisitions turning sour for Indian pharma firms, as happened in the case of Dr Reddy's acquisition of Betapharm of Germany for Rs 2,250 crore (Rs 22.5 billion).
The S&P BSE Sensex surged 364 points to end at 24,607 and the Nifty50 soared 107 points to close at 7,476.
Drug firm MSD has decided to enter into voluntary licensing agreements for investigational oral antiviral drug candidate 'Mmolnupiravir', which is being studied for the treatment of Covid-19, with Indian drug firms Sun Pharma, Cipla, Dr Reddy's, Emcure Pharma and Hetero Labs, its Indian arm said on Tuesday.
Markets closed in the red on domestic worries.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
Participants will watch out for the Brexit poll outcome in the late morning trades tomorrow.
In a range-bound trading, the BSE benchmark Sensex ended a shade higher by 1.57 points in the special 90-minute trading today as funds refrained from making any major commitments in the absence of global cues.
Russia's central bank early on Tuesday raised interest rates to 17 per cent to counter the 50 per cent rouble fall in six months.
Investors lost Rs 2 trillion as Sensex crashed on Tuesday.
While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.
Indian Pharma majors are looking at different strategies to boost their global business.
When Prashanth Reddy's father was in an ICU he could not find a lab that would deliver a blood infection test report in 24 hours. That's where iGenetic Diagnostics, which uses molecular techniques next generation sequencing, came in.
However, experts caution that investors should not expect the big returns they got from the sector between March and September 2020.
Alkem, the largest manufacturer of Fructo-Oligo Saccharides, which helps the growth of good probiotic bacteria, is planning to roll out more products in the national and global markets, said Sharad.
Asia's falling stocks have triggered an exodus of funds from the region.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Adani Ports, BHEL, Tata Motors, ONGC, Mahindra & Mahindra and Tata Steel were the top losers.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The 30-share Sensex dropped 298 points to end at 27,209 and the 50-share Nifty has lost 93 points to end at 8,174.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances